Organization
Centre Leon Berard
37 clinical trials
17 abstracts
Abstract
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Org: Medical Oncology Department, Rene Gauducheau Cancer Center, Institut De Cancerologie D'Ouest Centre Paul Papin, Hôpital Saint Grégoire, Faculté de Médecine Paris-Sud,
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Abstract
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.Org: National Taiwan University Hospital and National Taiwan University Cancer Center, Seoul National University Bundang Hospital, Istituto Europeo di Oncologia, Osaka International Cancer Institute, Osaka, Japan, Peking Union Medical College Hospital,
Clinical trial
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2019-11-01
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,
Clinical trial
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard ChemotherapyStatus: Completed, Estimated PCD: 2020-05-16
Clinical trial
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase I/II Study to Evaluate the Safety Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Standard AZACITIDINE+ VENETOCLAX in Patients With Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2027-03-28
Clinical trial
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients : AVapritinib Real-life observatTORyStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary CancerStatus: Recruiting, Estimated PCD: 2028-07-26
Clinical trial
A Multicentric, Single Arm, Open-label, Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal CancerStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 YearsStatus: Active (not recruiting), Estimated PCD: 2029-06-01
Clinical trial
A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
KETACANCER: Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCCStatus: Completed, Estimated PCD: 2023-02-06
Clinical trial
A Randomised, Comparative, Prospective, Multicentre Study of the Efficacy of Nivolumab + Ipilimumab Versus Pazopanib Alone in Patients With Metastatic or Unresectable Advanced Sarcoma of Rare Subtype (RAR-Immune)Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm SeminomasStatus: Recruiting, Estimated PCD: 2025-09-06
Clinical trial
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESSStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With EpendymomaStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)Status: Not yet recruiting, Estimated PCD: 2028-05-15
Clinical trial
Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard TreatmentStatus: Recruiting, Estimated PCD: 2026-07-21
Clinical trial
A Single-center, Prospective Profiling Program of Advanced/Metastatic Pancreatic Cancer PatientsStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Multicenter Phase II Study Evaluating the Efficacy and Safety of the Combination of Durvalumab With Etoposide and Platinum as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas (LCNECs) of the LungStatus: Not yet recruiting, Estimated PCD: 2028-09-01
Clinical trial
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer.Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesStatus: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Multicentric, Single Arm, Phase II Trial Assessing the Efficacy of Niraparib as First Line Therapy for Patients With Metastatic Homologous Repair-deficient Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6Status: Completed, Estimated PCD: 2022-11-05
Clinical trial
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.Status: Active (not recruiting), Estimated PCD: 2024-02-15
Clinical trial
A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard ImmunotherapiesStatus: Recruiting, Estimated PCD: 2026-02-24
Clinical trial
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced CancerStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma.Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and SunitinibStatus: Recruiting, Estimated PCD: 2023-09-01
Abstract
Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Centre Leon Berard, Lyon I University, Lyon, France, IUCT-Oncopole Toulouse,
Abstract
Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.Org: Centre Leon Berard, Lyon I University, Hôpital Européen Georges Pompidou, Sorbonne University and Saint-Antoine Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.Org: H. Lee Moffitt Cancer Center and Research Institute, Onc.AI, Ohio State University Comprehensive Canvcer Hospital, University of Rochester Medical Center Department of Neurobiology and Anatomy, Earle A Chiles Research Institute,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Gustave Roussy Cancer Center, ICO Institut de Cancerologie de l'Ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France,
Abstract
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).Org: Gustave Roussy Département d'Organisation du Parcours Patient, Institut Paoli Calmettes, Centre Hospitalier Lyon Sud, ICM Val d'Aurelle, CHU Nantes-Department of Hepato-Gastroenterology,
Abstract
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, APHP.Centre - Université Paris Cité, Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment.Org: ArianaPharma, Centre Leon Berard, Centre Léon Bérard, AP-HP at Saint-Louis Hospital, University Claude Bernard Lyon 1,
Abstract
Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019).Org: Centre Léon Bérard, CHI Créteil, Rouen University Hospital, Hopital Foch, Nord University Hospital,
Abstract
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.Org: Centre Léon-Bérard, Centre Léon Bérard, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.Org: HIA SAINTE ANNE, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
CAROLINE study: Incidence and characterization of melanoma in French Polynesia.Org: Gustave Roussy Institute, Hopital Europeean Georges Pompidou, Universite Paris Cite, CHU Poitiers - Jean Bernard Hôpital, Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,